Cancer pathology

United Breast Cancer Foundation Celebrates with Twisted Pink at 'An Evening Inspired' Gala

Retrieved on: 
Tuesday, July 20, 2021
Cancer, Breast cancer, Medical specialties, Cancer pathology, Metástasis, Oncology, Metastatic breast cancer, The Breast

HUNTINGTON, N.Y., July 20, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) was proud to be the Title Patient Sponsor of Twisted Pink's 7th Annual Gala, "An Evening Inspired" , held on July 9th at Churchill Downs Millionaires Row, in Louisville, KY.

Key Points: 
  • HUNTINGTON, N.Y., July 20, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) was proud to be the Title Patient Sponsor of Twisted Pink's 7th Annual Gala, "An Evening Inspired" , held on July 9th at Churchill Downs Millionaires Row, in Louisville, KY.
  • The Gala, with more than 400 in attendance, was an evening of hope, celebration and positivity, aiming to raise funds for metastatic breast cancer research.
  • Twisted Pink's mission of raising funds for metastatic breast cancer research benefits patients with breakthroughs.
  • "It was a wonderful evening filled with hope, compassion, the sharing of many stories regarding breast cancer journeys, and a vision for a better tomorrow for individuals affected by breast cancer."

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Retrieved on: 
Tuesday, June 1, 2021
Tumor, Cancer pathology, Oncology, Tumor microenvironment, Metástasis, Branches of biology

This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.

Key Points: 
  • This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.
  • TGF plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment (TME).
  • The integrins v6 and v8 are expressed by cancer cells, and v6 is also expressed on epithelial cells in fibrotic diseases.
  • Corbus believes targeting both integrins at once is a rational approach to treating fibrotic diseases and carcinomas.

$26.45 Billion Circulating Tumor Cells Market by Technology; Application; Product; Specimen - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, Oncology, Medicine, Clinical medicine, Medical specialties, Oncology, Anatomical pathology, Cancer pathology, Cancer, Metástasis, Liquid biopsy, Circulating tumor cell, Biopsy, Melanoma

Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.

Key Points: 
  • Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.
  • Currently, circulating tumor cell-based screening and analysis are at a nascent market stage.
  • The market dominance of cell-free DNA units over circulating tumor cells in cancer diagnosis has led to less share in clinical applications.
  • This high market growth is due to the fact that most of the products currently being on the market are primarily designed for research settings.

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

Retrieved on: 
Friday, April 9, 2021
Oncology, Medical devices, Health, Other Health, Radiology, Biotechnology, Cancer, Clinical medicine, Medicine, Oncology, Cancer treatments, Gynaecological cancer, Cancer pathology, Metástasis, Alternating electric field therapy, Brain metastasis, Chemotherapy, Ovarian cancer

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.
  • Research spanning seven solid tumor types confirms the anti-mitotic effect of Tumor Treating Fields and further explores downstream effects to identify optimal use of Tumor Treating Fields, including the role of Tumor Treating Fields-induced immunogenic cell death.
  • H. Ben Atya (Tumor Biology)
    (Poster #: 3071) A method for infratentorial structures segmentation for tumor treating fields treatment planning.
  • Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment

Retrieved on: 
Thursday, April 1, 2021
Cancer, Medicine, Clinical medicine, Oncology, Cancer pathology, Tumor, Tumor microenvironment, Metástasis, Treatment of cancer, Cancer treatments, Cancer research, Metastatic breast cancer

In a new study published today inNature Communications, Cello Therapeutics shows how semisynthetic nanoparticles coated in platelet membrane can effectively inhibit tumor growth and metastasis in multiple mouse models of solid tumors.

Key Points: 
  • In a new study published today inNature Communications, Cello Therapeutics shows how semisynthetic nanoparticles coated in platelet membrane can effectively inhibit tumor growth and metastasis in multiple mouse models of solid tumors.
  • Previous studies have shown that platelets naturally bind to both cancer cells and components of the tumor microenvironment.
  • Localized intratumoral injection of PNP-R848 effectively eliminated or inhibited tumor growth in two separate mouse models of cancer.
  • About Cello Therapeutics Inc.: Founded in 2016 in San Diego, CA, Cello is an emerging biotechnology company focused on developing novel nanoparticle delivery platforms for cancer treatment.

Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis

Retrieved on: 
Monday, March 22, 2021
Cancer, Oncology, Cancer pathology, Metástasis, CRISPR gene editing, Shuguang Zhang

Metastasisthe spreading of cancer cells from the initial tumor site to surrounding tissues and distant organsis responsible for the vast majority of cancer deaths.

Key Points: 
  • Metastasisthe spreading of cancer cells from the initial tumor site to surrounding tissues and distant organsis responsible for the vast majority of cancer deaths.
  • In an ongoing co-development research program, Avalon and the laboratory of Dr. Shuguang Zhang at MITs Media Lab have developed a novel approach to potentially block the signals that cancer cells require to metastasize in order to prevent cancer spread and death.
  • Avalon and MIT researchers are also working on a second approachcombining the QTY technology with the CRISPR-Cas9 gene editing system to re-program cell types that typically stimulate nearby cancer cells to spread, thereby deterring cancer metastasis.
  • This new endeavor builds on our collaboration with MIT using the QTY code technology to develop innovative therapies for cancer metastasis, stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.

Catenin Beta 1 Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Pharmaceutical, Health, Clinical trials, Cancer pathology, Oncology, Amyloidosis, PRNP, Metástasis, Medicine, Clinical medicine, Health

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients

Key Points: 

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.

CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

Retrieved on: 
Monday, March 15, 2021
Oncology, Cancer pathology, Metástasis

HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC.

Key Points: 
  • HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC.
  • Interested parties are invited to attend the virtual conference and access exclusive content by becoming an M-Vest member and registering HERE.
  • To learn more about the event, please visit the conference website: Emerging Growth Virtual Conference .
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.

CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021
Oncology, Cancer pathology, Metástasis, Central nervous system

HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Key Points: 
  • HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
  • In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website here .
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.

Kanazawa University research: Going the distance--insights into how cancer cells spread

Retrieved on: 
Monday, February 8, 2021
Branches of biology, Medicine, Oncology, Cancer pathology, Stem cells, Metástasis, Cancer, Induced stem cells, Cancer stem cell

Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.

Key Points: 
  • Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.
  • To replicate polyclonal metastasis, AP cells were then co-transplanted with AKTP cells, and voila, both cell types indeed moved into the livers.
  • Instead, when AP cells were injected into the blood (without prior exposure to the AKTP cells) they could not metastasize.
  • Next, AKTP cells within the liver tumors were killed to see how closely that affected the AP cells.